MINNEAPOLIS, June 10, 2021
CVRx® Announces First Clinical Procedure with a New Ultrasound-Guided Implant Approach, the Latest Advancement in Barostim™ for the Treatment of Heart Failure Symptoms
Author: Jonathan McLellan
Response by Sex in Patient-Centered Outcomes With Baroreflex Activation Therapy in Systolic Heart Failure
JACC: HEART FAILURE – JUNE 2021
Cost-impact analysis of baroreflex activation therapy in chronic heart failure patients in the United States
March 26, 2021
CVRx® Appoints New Chief Marketing Officer and Vice President of European Sales and Marketing
Effective January 5, 2021
CVRx® BAROSTIM Therapy Receives CMS Approval for Transitional Pass-Through Payment Status
Effective December 2, 2020
CVRx® Announces New CFO and Acceleration of Barostim Therapy Commercialization Efforts
Effective November 18, 2020
CVRx’s BAROSTIM NEO™ Receives CMS NTAP
Effective October 1, 2020